The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of benign disease increases markedly with age. There is evidence, however, that free-to-total PSA ratio (%fPSA) and human kallikrein 2 (hK2) more closely reflect the malignant process. We te...
Autors principals: | Vickers, A, Ulmert, D, Serio, A, Björk, T, Scardino, P, Eastham, J, Berglund, G, Lilja, H |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
2007
|
Ítems similars
-
Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
per: Ulmert, D, et al.
Publicat: (2008) -
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
per: Ulmert, D, et al.
Publicat: (2008) -
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
per: Lilja, H, et al.
Publicat: (2007) -
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
per: Berglund Göran, et al.
Publicat: (2008-02-01) -
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
per: Vickers, A, et al.
Publicat: (2010)